| 发明名称 |
Methods for identifying analgesic agents |
| 摘要 |
The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations. |
| 申请公布号 |
US9278088(B2) |
申请公布日期 |
2016.03.08 |
| 申请号 |
US201313860810 |
申请日期 |
2013.04.11 |
| 申请人 |
Xenon Pharmaceuticals Inc. |
发明人 |
MacDonald Marcia;Samuels Mark;Sherrington Robin;Goldberg Yigal Paul |
| 分类号 |
A61K31/00;A61K31/40;A01N43/38;C07H21/04;A61K31/407;C12Q1/68 |
主分类号 |
A61K31/00 |
| 代理机构 |
|
代理人 |
Olstein Elliot M.;Grant Alan J. |
| 主权项 |
1. A method of treating pain in a human having a gain of function nucleotide polymorphism in an SCN9A gene that results in the R1150W mutation in SCN9A polypeptide, comprising administering to said human a sodium channel blocking agent selected from Compound A and a chemical analog of Compound A that selectively inhibits the activity of the SCN9A polypeptide. |
| 地址 |
Burnaby, B.C. CA |
